Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans—An integrated vaccinomics approach

Nain, Zulkar; Karim, Mohammad Minnatul; Sen, Monokesh Kumer; Adhikari, Utpal

doi:10.1016/j.molimm.2020.02.009

Cited by 63 publications

(66 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The generation and increase of plasma cells were also documented.Furthermore, B and T cell populations decreased along with immunogen levels. These data is comparable to previous investigations that have been focused on vaccine development against Mycobacterium ulcerans[46] and filarial diseases[56], as well as are in agreement, at least partially, with a recent study that demonstrated a positive correlation between robust CD4+ THC responses with anti-SARS-CoV-2 IgG and IgA titres of COVID-19 convalescent patients[57]. These immune responses were directed to the SARS-CoV-2 S glycoprotein[57].…”

supporting

confidence: 91%

“…To further characterize the potential immune response of the multi-epitope vaccine, immune simulations were performed using the C-ImmSim server (http://150.146.2.1/C-IMMSIM/index.php) [45]. Three injections were applied four weeks apart as described previously [46]. Furthermore, 12 injections were applied four weeks apart to simulate repeated exposure to potential immunogen.…”

Section: In Silico Immune Response Simulationsmentioning

confidence: 99%

See 1 more Smart Citation

A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein

Marchan

2020

Preprint

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19) represents a new global threat demanding a multidisciplinary effort to fight its etiological agent—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this regard, immunoinformatics may aid to predict prominent immunogenic regions from critical SARS-CoV-2 structural proteins, such as the spike (S) glycoprotein, for their use in prophylactic or therapeutic interventions against this rapidly emerging coronavirus. Accordingly, in this study, an integrated immunoinformatics approach was applied to identify cytotoxic T cell (CTC), T helper cell (THC), and Linear B cell (BC) epitopes from the S glycoprotein in an attempt to design a high-quality multi-epitope vaccine. The best CTC, THC, and BC epitopes showed high viral antigenicity, lack of allergenic or toxic residues, and suitable HLA-viral peptide interactions. Remarkably, SARS-CoV-2 receptor-binding domain (RBD) and its receptor-binding motif (RBM) harbour several potential epitopes. The structure prediction, refinement, and validation data indicate that the multi-epitope vaccine has an appropriate conformation and stability. Three conformational epitopes and an efficient binding between Toll-like receptor 4 (TLR4) and the vaccine model were observed. Importantly, the population coverage analysis showed that the multi-epitope vaccine could be used globally. Notably, computer-based simulations suggest that the vaccine model has a robust potential to evoke and maximize both immune effector responses and immunological memory to SARS-CoV-2. Further research is needed to accomplish with the mandatory international guidelines for human vaccine formulations.Graphical Abstract

show abstract

supporting

confidence: 91%

Section: In Silico Immune Response Simulationsmentioning

confidence: 99%

A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein

Marchan

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The HTLs helps to activate CTLs together with other immune cells upon various types of cytokines release i.e., IFN-γ, interleukin-4 and interleukin-10 [17, 72]. Thus, HTL epitopes that induce cytokines are vital for the progress of vaccines or immunotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…Now a days, availability of genomic information, advance software and immunological data sets could greatly facilitate researchers to identify the effective epitopes from pathogens’ proteins that can be used to develop active sub-unit vaccines [12-15]. The subunit vaccine contains the fragments of antigenic proteins of pathogen that can trigger an immune response against the target pathogen [16, 17]. In recent studies, few candidate vaccine constructs were reported against MERS-CoV [18], Chikungunya virus [19], Ebola virus [20], Zika virus [21], HCV [22], Flavivirus [23] and Cytomegalovirus [24] with promising results.…”

Section: Introductionmentioning

confidence: 99%

“…The availability of genomic, software algorithms and immunological data has facilitated scientists to identify the effective epitopes that can be used to develop active subunit vaccines 12, 13 . The subunit vaccine contains the fragments of antigenic proteins that can mimic the presence of the natural pathogen and cause an immune response to the target pathogen 14, 15 . The design of the vaccine candidate against chikungunya, MERS virus, Ebola virus and Zika has produced promising results 16–19 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Qamar¹,

Rehman

Ashfaq

et al. 2020

Preprint

View full text Add to dashboard Cite

1Coronavirus disease 2019 (COVID-19) associated pneumonia caused by severe acute respiratory 2 coronavirus 2 (SARS-COV-2) was first reported in Wuhan, China in December 2019. Till date, 3 no vaccine or completely effective drug is available for the cure of COVID-19. Therefore, an 4 effective vaccine against SARS-COV-2 is needed to be design. This study was conducted to 5 design an effective multi-epitope vaccine (MEV) against SARS-COV-2. Seven antigenic 6 proteins were taken as a target and epitopes (B cell, IFNγ and T cell) were predicted. Highly 7 antigenic and overlapping epitopes were shortlisted. Selected T cell epitopes indicated significant 8 interactions with the HLA-binding alleles and 99.29% coverage of the world's population. 9 Finally, 505 amino acids long MEV was designed by connecting sixteen MHC class I and twelve 1 0 MHC class II epitopes with suitable linkers and adjuvant. Linkers and adjuvant were added to 1 1 enhance the immunogenicity response of the vaccine. The allergenicity, physiochemical 1 2 properties, antigenicity and structural details of MEV were analyzed in order to ensure safety and 1 3 immunogenicity. MEV construct was non-allergenic and antigenic. Molecular docking 1 4 demonstrated a stable and strong binding affinity of MEV with TLR3 and TLR8. Codon 1 5 optimization and in silico cloning ensured increased expression in the Escherichia coli K-12 1 6system. However, to ensure its safety and immunogenic profile, the proposed vaccine needs to be 1 7 experimentally validated. 1 8

show abstract

Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches

Samad¹,

Meghla²,

Nain

et al. 2022

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans—An integrated vaccinomics approach

Cited by 63 publications

References 104 publications

A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein

A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches

Contact Info

Product

Resources

About